Open AccessLaser‐engineered dissolving microneedle arrays for protein delivery: potential for enhanced intradermal vaccination
Author(s) -
McCrudden Maelíosa T. C.,
Torrisi Barbara M.,
AlZahrani Sharifah,
McCrudden Cian M.,
Zaric Marija,
Scott Christopher J.,
Kissenpfennig Adrien,
McCarthy Helen O.,
Donnelly Ryan F.
Publication year - 2015
Publication title -
journal of pharmacy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.745
H-Index - 118
eISSN - 2042-7158
pISSN - 0022-3573
DOI - 10.1111/jphp.12248
Subject(s) - transdermal , ovalbumin , vaccination , immunology , antigen , hypodermic needle , medicine , materials science , chemistry , pharmacology , psychiatry , syringe
Objectives We aimed to highlight the utility of novel dissolving microneedle ( MN )‐based delivery systems for enhanced transdermal protein delivery. Vaccination remains the most accepted and effective approach in offering protection from infectious diseases. In recent years, much interest has focused on the possibility of using minimally invasive MN technologies to replace conventional hypodermic vaccine injections. Methods The focus of this study was exploitation of dissolving MN array devices fabricated from 20% w/w poly(methyl vinyl ether/maleic acid) using a micromoulding technique, for the facilitated delivery of a model antigen, ovalbumin ( OVA ). Key findings A series of in‐vitro and in‐vivo experiments were designed to demonstrate that MN arrays loaded with OVA penetrated the stratum corneum and delivered their payload systemically. The latter was evidenced by the activation of both humoral and cellular inflammatory responses in mice, indicated by the production of immunoglobulins ( IgG , IgG 1, IgG2a ) and inflammatory cytokines, specifically interferon‐gamma and interleukin‐4. Importantly, the structural integrity of the OVA following incorporation into the MN arrays was maintained. Conclusion While enhanced manufacturing strategies are required to improve delivery efficiency and reduce waste, dissolving MN are a promising candidate for ‘reduced‐risk’ vaccination and protein delivery strategies.